Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

Trial Profile

A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza HA vaccine (Flubio)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo
  • Most Recent Events

    • 04 Nov 2015 New source identified and integrated; Japan Pharmaceutical Information Center - Clinical Trials Information record (JapicCTI142493)
    • 04 Nov 2015 New trial record
    • 28 Oct 2015 Primary endpoint has been met. (The difference between the seroconversion rates and the ratio of GMTs of HI antibody titer against three vaccine stains at Day 21), as per an article published in the Vaccine.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top